Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senti Biosciences HoldingsSNTI +1.53%13 3-Year EBITDA Growth Rate is 50.70% as of Jun. 2026. GuruFocus rates SNTI with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 1,122 Biotechnology companies, Senti Biosciences Holdings ranks better than 86.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Senti Biosciences Holdings was 50.70% per year. The lowest was -38.50% per year. And the median was -13.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Senti Biosciences Holdings 3-Year EBITDA Growth Rate Related Terms
SNTI vs KPRX, PDSB, TOVX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Senti Biosciences Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.70% mean?
Senti Biosciences Holdings (SNTI) has a 3-Year EBITDA Growth Rate of 50.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Senti Biosciences Holdings and its competitors. According to the industry distribution chart, Senti Biosciences Holdings ranks #156 out of 1122 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Senti Biosciences Holdings' 3-Year EBITDA Growth Rate too high?
Senti Biosciences Holdings' current 3-Year EBITDA Growth Rate is 50.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.75. Senti Biosciences Holdings' value of 50.70% is 243.7% above this industry median. Based on the distribution chart, Senti Biosciences Holdings ranks #156 out of 1122 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' 3-Year EBITDA Growth Rate compare to KPRX and PDSB?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #156 out of 1122 companies for 3-Year EBITDA Growth Rate. This places Senti Biosciences Holdings in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.75. Senti Biosciences Holdings' value of 50.70% is 243.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senti Biosciences Holdings's current 3-Year EBITDA Growth Rate of 50.70% is 243.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Senti Biosciences Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current 3-Year EBITDA Growth Rate is 50.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current 3-Year EBITDA Growth Rate of 50.70%. The current 3-Year EBITDA Growth Rate is 50.70% and 243.7% above the Biotechnology industry median of 14.75. Senti Biosciences Holdings' overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current 3-Year EBITDA Growth Rate is 50.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
13GF Score
Get the complete analysis for SNTI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
